Intellia Therapeutics Announces Closing of Initial Public Offering
Intellia Therapeutics Announces Pricing of Initial Public Offering
Intellia Therapeutics Appoints Perry Karsen as Chairman of its Board of Directors
Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics
Intellia Founders Awarded Distinguished Alpert Prize
Intellia Therapeutics Launches New Division to Accelerate Ex Vivo Programs with CRISPR/CAS9
Intellia Therapeutics Appoints Caroline Dorsa To Company’s Board Of Directors
Joint Statement of Intellia Therapeutics & CRISPR Therapeutics: Position Regarding Human Germline Gene Editing
FierceBiotech names Intellia Therapeutics as one of its “Fierce 15” Biotech Companies of 2015
Intellia Therapeutics Secures $70 Million in Series B Financing